We are live on
!
Find out more
Walleye Capital Portfolio holdings
AUM
$24B
1-Year Est. Return
37.67%
This Fund
S&P 500
This Quarter
Est. Return
-4.15%
1 Year Est. Return
+37.67%
3 Year Est. Return
+98.01%
5 Year Est. Return
+160%
10 Year Est. Return
–
AUM
$1.68B
AUM Growth
+$769M
(+84%)
Cap. Flow
+$831M
Cap. Flow
% of AUM
49.48%
Top 10 Holdings %
Top 10 Hldgs %
8.16%
Holding
2,474
New
799
Increased
624
Reduced
373
Closed
629
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$2.65M |
| 2 |
NFINU
Netfin Acquisition Corp. Unit
NFINU
|
+$2.57M |
| 3 |
ABMD
Abiomed Inc
ABMD
|
+$2.42M |
| 4 |
Humana
HUM
|
+$2.37M |
| 5 |
Cigna
CI
|
+$2.29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JFKKU
8i Enterprises Acquisition Corp Unit
JFKKU
|
+$1.58M |
| 2 |
GIX.U
GigCapital2, Inc.
GIX.U
|
+$1.35M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$1.31M |
| 4 |
CHAC.U
Chardan Healthcare Acquisition Corp.
CHAC.U
|
+$1.27M |
| 5 |
Artisan Partners
APAM
|
+$1.24M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 1.91% |
| 2 | Technology | 1.1% |
| 3 | Consumer Discretionary | 1.05% |
| 4 | Communication Services | 0.58% |
| 5 | Materials | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
AbbVie
ABBV
$454B
| $18.6M | 1.11% |
245,700
+169,400
| +222% | +$11.6M |
|
2
CALL
Amgen
AMGN
$201B
| $18M | 1.07% |
92,900
+83,600
| +899% | +$16M |
|
3
CALL
Vertex Pharmaceuticals
VRTX
$120B
| $15M | 0.89% |
88,600
+61,200
| +223% | +$10.8M |
|
4
CALL
Palo Alto Networks
PANW
$265B
| $13.7M | 0.82% |
403,200
+318,600
| +377% | +$11.3M |
|
5
CALL
Eli Lilly
LLY
$1.06T
| $13.1M | 0.78% |
116,900
+77,000
| +193% | +$8.57M |
|
6
CALL
IQVIA
IQV
$34.6B
| $12.8M | 0.76% |
85,400
+47,900
| +128% | +$7.45M |
|
7
CALL
Zoetis
ZTS
$31.3B
| $12.5M | 0.74% |
100,200
+49,600
| +98% | +$5.99M |
|
8
CALL
Johnson & Johnson
JNJ
$624B
| $11.2M | 0.67% |
86,900
+73,300
| +539% | +$9.66M |
|
9
CALL
Thermo Fisher Scientific
TMO
$213B
| $11.1M | 0.66% |
38,200
+21,000
| +122% | +$6.01M |
|
10
CALL
Southern Company
SO
$109B
| $11.1M | 0.66% |
179,500
+100,000
| +126% | +$5.8M |
|
11
CALL
Jazz Pharmaceuticals
JAZZ
$16B
| $10.8M | 0.64% |
84,000
+62,900
| +298% | +$8.43M |
|
12
CALL
Merck
MRK
$322B
| $10.6M | 0.63% |
131,734
+67,701
| +106% | +$5.43M |
|
13
CALL
Archer Daniels Midland
ADM
$41.6B
| $9.84M | 0.59% |
239,600
+183,800
| +329% | +$7.32M |
|
14
CALL
Regeneron Pharmaceuticals
REGN
$68.3B
| $9.82M | 0.58% |
35,400
+24,400
| +222% | +$7.22M |
|
15
CALL
Lowe's Companies
LOW
$113B
| $9.82M | 0.58% |
89,300
+53,700
| +151% | +$5.67M |
|
16
CALL
Gilead Sciences
GILD
$162B
| $9.62M | 0.57% |
151,700
+128,700
| +560% | +$8.41M |
|
17
CALL
Agilent Technologies
A
$39.5B
| $9.02M | 0.54% |
117,700
+103,700
| +741% | +$7.48M |
|
18
CALL
CVS Health
CVS
$136B
| $8.64M | 0.51% |
137,000
+116,800
| +578% | +$6.92M |
|
19
CALL
Bristol-Myers Squibb
BMY
$126B
| $8.44M | 0.5% |
166,500
+57,000
| +52% | +$2.68M |
|
20
CALL
Target
TGT
$61.1B
| $8.06M | 0.48% |
75,400
+70,700
| +1,504% | +$6.73M |
|
21
CALL
McDonald's
MCD
$187B
| $7.84M | 0.47% |
36,500
+30,600
| +519% | +$6.56M |
|
22
CALL
Walmart Inc
WMT
$863B
| $7.76M | 0.46% |
196,200
+100,800
| +106% | +$3.8M |
|
23
CALL
Intercontinental Exchange
ICE
$81B
| $7.65M | 0.46% |
82,900
+48,900
| +144% | +$4.46M |
|
24
CALL
Sempra
SRE
$61.1B
| $7.42M | 0.44% |
100,600
+11,600
| +13% | +$812K |
|
25
CALL
Lumen
LUMN
$6.73B
| $7.34M | 0.44% |
588,300
+155,600
| +36% | +$1.85M |
|
Similar funds
JG
SC
OAG
CS
Walleye Capital's Q3 2019 Portfolio in Review
As of Q3 2019, Walleye Capital held 2,474 positions worth $1.68B, up 84% from $910M the previous quarter. Its ten largest holdings account for 8.2% of the portfolio.
Walleye Capital deployed $831M of net new capital in Q3 2019, opening 799 new positions and adding to 624 existing holdings. Its largest new stake was Meta Platforms (Facebook): 13,918 shares worth $2.48M.
By sector, the portfolio is most concentrated in Healthcare at 1.9% of assets, up from 1.8% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Arqule Inc, an estimated $1.22M trimmed.
- Walleye Capital's largest Q3 2019 buy was Meta Platforms (Facebook): 13,918 shares worth $2.48M.
- Walleye Capital added most to Abiomed Inc in Q3 2019, an estimated $2.42M increase.
- Walleye Capital's biggest Q3 2019 reduction was Arqule Inc, cutting an estimated $1.22M.
- Walleye Capital fully exited 8i Enterprises Acquisition Corp Unit in Q3 2019, selling an estimated $1.58M.
- Walleye Capital's ten largest holdings make up 8.2% of its $1.68B portfolio in Q3 2019.
- Walleye Capital opened 799 new positions and closed 629 in Q3 2019.
- Walleye Capital's portfolio value rose 84% quarter-over-quarter to $1.68B.
Based on Walleye Capital's 13F filing for Q3 2019, filed 14 Nov 2019.